In addition, the prevalence of pathogenic CFTR GVs in the colorectal cancer population was significantly higher than expected suggesting an increased cancer risk not only in cystic fibrosis patients, but also in heterozygous CFTR GV carriers [7]. This evidence concerns the gene CFTR and cystic fibrosis.